ASA404 fails second late-stage lung cancer trial
Novartis and its partner Antisoma announced that an interim analysis of data from a late-stage trial showed that vadimezam (ASA404) was unlikely to provide any benefit as a second-line treatment for patients with non-small-cell lung cancer. As a result, Novartis indicated that it would halt development of the compound, which was designed to inhibit angiogenesis.
Novartis and its partner Antisoma announced that an interim analysis of data from a late-stage trial showed that vadimezam (ASA404) was unlikely to provide any benefit as a second-line treatment for patients with non-small-cell lung cancer. As a result, Novartis indicated that it would halt development of the compound, which was designed to inhibit angiogenesis.
The ATTRACT-2 study enrolled patients with advanced NSCLC whose disease had progressed after first-line therapy. In ATTRACT-1, ASA404 failed to demonstrate a survival benefit in previously untreated patients with NSCLC when used in combination with chemotherapy.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies
June 13th 2024"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."
